Bacthera

What Bacthera does

Bacthera is a Basel, Switzerland-based contract development and manufacturing organization (CDMO) founded in 2019 that operates in the Live Biotherapeutic Products (LBP) and microbiome contract manufacturing segment. The company is positioned as a specialized manufacturing partner for pharmaceutical and biotechnology customers developing live biotherapeutic products and microbiome-based therapeutics, addressing manufacturing capacity constraints, regulatory compliance for live microbial products, and scalability challenges associated with this emerging therapeutic modality.

The company's underlying offering centers on contract manufacturing services for live biotherapeutic products, providing differentiated capabilities in a niche where most traditional CDMOs lack the requisite expertise in handling live microbial agents under pharmaceutical-grade quality standards. Its target customer segment is horizontal — pharmaceutical and biotechnology companies developing microbiome-based drugs — with pain points centered on manufacturing capacity, regulatory complexity around live microbial products, and scale-up challenges. The company operates with a headcount of 51–100 employees as a private, for-profit entity.

Bacthera participates in the global Live Biotherapeutic Products and Microbiome Contract Manufacturing market, which is forecast to reach $1,456.9 million by 2034. Detailed information regarding specific product lines, named customers, contract structures, management team composition, funding history, certifications, and operational footprint beyond Basel was not available in accessible source data, and the company's primary website returned only a verification page during data collection, limiting the depth of verifiable disclosures.

Name

Bacthera

Website

https://bacthera.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Bacthera is a Basel, Switzerland-based contract development and manufacturing organization specializing in Live Biotherapeutic Products and microbiome-based therapeutics. The company serves pharmaceutical and biotechnology customers requiring specialized manufacturing capabilities for live microbial products.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Live biotherapeutic manufacturing
• Microbiome contract manufacturing
• Biopharmaceutical CDMO services
• Microbial therapeutics production
• Live biopharmaceutical development

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Core offering

Bacthera is a contract development and manufacturing partner (CDMO) that provides specialized manufacturing services for Live Biotherapeutic Products (LBP) and microbiome-based therapeutics. The company serves biotech and pharmaceutical customers developing live microbial and microbiome-based drugs, supporting development, production, and scalability of these emerging therapeutic products.

Product overview

Bacthera operates in the Live Biotherapeutic Products (LBP) and Microbiome Contract Manufacturing industry. Based on the available source data, no specific product names, modules, or detailed service offerings are provided.

Differentiator

Problem solved

Functional benefit

Products and services

• Live Biotherapeutic Products (LBP) Contract Manufacturing Contract manufacturing service for Live Biotherapeutic Products, providing biotech and pharmaceutical customers with specialized production capacity for live microbial drug substances used in microbiome-based therapeutics development and supply.
• Microbiome-based Therapeutics Contract Manufacturing Contract development and manufacturing service supporting production of microbiome-based therapeutics, addressing manufacturing capacity, regulatory compliance, and scalability needs for companies developing live microbial and microbiome drugs.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Expansion highlights1 record

Direct peers

• Lonza: Global biologics CDMO with extensive microbial fermentation and drug substance capabilities. Lonza is the most directly comparable peer given overlap in LBP-adjacent microbial manufacturing, and is also reportedly one of Bacthera's parent/JV backers, giving it both competitive and equity alignment.
• AGC Biologics: Biologics CDMO offering microbial and mammalian-based contract manufacturing. Its microbial fermentation services and experience with live biotherapeutics make it a close functional peer to Bacthera in the LBP and microbiome manufacturing space.
• Recipharm: Contract development and manufacturing organization with biologics and complex drug product capabilities, including services relevant to live biotherapeutic and microbiome-derived products. Comparable in size and CDMO service profile to Bacthera.
• Boehringer Ingelheim BioXcellence: Biologics CDMO arm of Boehringer Ingelheim offering contract manufacturing for recombinant proteins, cell culture, and microbial-derived biopharmaceuticals. Overlaps with Bacthera in serving biotech and pharma clients with complex biological manufacturing needs.

Broad incumbents

• WuXi Biologics: Large-scale biologics CDMO with microbial and cell culture manufacturing platforms. As a broad incumbent, it competes for outsourced biopharma manufacturing work that Bacthera also targets, and can extend into LBP/microbiome projects from its existing infrastructure.
• Catalent: Major global CDMO with biologics, sterile fill-finish, and oral dose capabilities. While broader than Bacthera, it competes for pharma and biotech outsourcing budgets and could expand into live biotherapeutic manufacturing as the modality matures.
• FUJIFILM Diosynth Biotechnologies: Biologics CDMO with microbial fermentation and cell culture capacity for vaccines, gene therapies, and recombinant proteins. Comparable to Bacthera on the contract manufacturing of biologically derived products, including microbial-based candidates.
• Charles River Laboratories: Provides contract development and manufacturing services for biologics and microbial-derived products, including CDMO offerings relevant to microbiome and LBP sponsors. Broader portfolio than Bacthera but with overlapping manufacturing capabilities.
• Samsung Biologics: Large biologics CDMO with significant mammalian and microbial manufacturing capacity. While primarily focused on monoclonal antibodies and recombinant proteins, its scale and CDMO services place it in the same competitive set for outsourced biopharma manufacturing.
• Thermo Fisher Scientific (Patheon/CDMO): Operates one of the largest global CDMO networks, including biologics manufacturing through Patheon and related businesses. Represents a broad incumbent competitor for outsourced pharma and biotech manufacturing services.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/BactheraAG

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bacthera